Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment

被引:530
作者
Correll, Christoph U. [1 ,2 ,3 ]
Schooler, Nina R. [4 ]
机构
[1] Zucker Hillside Hosp, Div Psychiat Res, Northwell Hlth, Glen Oaks, NY 11004 USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Psychiat & Mol Med, New York, NY USA
[3] Charite, Dept Child & Adolescent Psychiat, Berlin, Germany
[4] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
关键词
schizophrenia; negative symptoms; prevalence; clinical presentation; diagnosis; treatment; DOPAMINE D-3 RECEPTOR; COGNITIVE-BEHAVIORAL THERAPY; ANTIPSYCHOTIC-LIKE ACTIVITY; PHARMACOLOGICAL-TREATMENT; DOUBLE-BLIND; D3; RECEPTOR; HIGH-RISK; EFFICACY; METAANALYSIS; ANTAGONISM;
D O I
10.2147/NDT.S225643
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Schizophrenia is frequently a chronic and disabling disorder, characterized by heterogeneous positive and negative symptom constellations. The objective of this review was to provide information that may be useful for clinicians treating patients with negative symptoms of schizophrenia. Negative symptoms are a core component of schizophrenia that account for a large part of the long-term disability and poor functional outcomes in patients with the disorder. The term negative symptoms describes a lessening or absence of normal behaviors and functions related to motivation and interest, or verbal/emotional expression. The negative symptom domain consists of five key constructs: blunted affect, alogia (reduction in quantity of words spoken), avolition (reduced goal-directed activity due to decreased motivation), asociality, and anhedonia (reduced experience of pleasure). Negative symptoms are common in schizophrenia; up to 60% of patients may have prominent clinically relevant negative symptoms that require treatment. Negative symptoms can occur at any point in the course of illness, although they are reported as the most common first symptom of schizophrenia. Negative symptoms can be primary symptoms, which are intrinsic to the underlying pathophysiology of schizophrenia, or secondary symptoms that are related to psychiatric or medical comorbidities, adverse effects of treatment, or environmental factors. While secondary negative symptoms can improve as a consequence of treatment to improve symptoms in other domains (ie, positive symptoms, depressive symptoms or extrapyramidal symptoms), primary negative symptoms generally do not respond well to currently available antipsychotic treatment with dopamine D-2 antagonists or partial D-2 agonists. Since some patients may lack insight about the presence of negative symptoms, these are generally not the reason that patients seek clinical care, and clinicians should be especially vigilant for their presence. Negative symptoms clearly constitute an unmet medical need in schizophrenia, and new and effective treatments are urgently needed.
引用
收藏
页码:519 / 534
页数:16
相关论文
共 103 条
[91]  
Stahl S., 2013, Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, V4th
[92]   Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes [J].
Stahl, Stephen M. .
CNS SPECTRUMS, 2017, 22 (05) :375-384
[93]   10-YEAR COURSE OF SCHIZOPHRENIA - THE MADRAS LONGITUDINAL-STUDY [J].
THARA, R ;
HENRIETTA, M ;
JOSEPH, A ;
RAJKUMAR, S ;
EATON, WW .
ACTA PSYCHIATRICA SCANDINAVICA, 1994, 90 (05) :329-336
[94]  
Torrey E Fuller, 2012, Clin Schizophr Relat Psychoses, V5, P208, DOI 10.3371/CSRP.5.4.5
[95]   Psychological Interventions for Psychosis: A Meta-Analysis of Comparative Outcome Studies [J].
Turner, David Trevor ;
van der Gaag, Mark ;
Karyotaki, Eirini ;
Cuijpers, Pim .
AMERICAN JOURNAL OF PSYCHIATRY, 2014, 171 (05) :523-538
[96]   Integrated Psychosocial Treatment for Negative Symptoms [J].
Velligan, Dawn ;
Maples, Natalie ;
Roberts, David L. ;
Medellin, Elisa M. .
AMERICAN JOURNAL OF PSYCHIATRIC REHABILITATION, 2014, 17 (01) :1-19
[97]   A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia [J].
Velligan, Dawn I. ;
Roberts, David ;
Mintz, Jim ;
Maples, Natalie ;
Li, Xueying ;
Medellin, Elisa ;
Brown, Matt .
SCHIZOPHRENIA RESEARCH, 2015, 165 (2-3) :175-180
[98]  
Velligan DI, 2011, PSYCHIAT SERV, V62, P558, DOI 10.1176/ps.62.5.pss6205_0558
[99]   Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis [J].
Velthorst, Eva ;
Nieman, Dorien H. ;
Becker, Hiske E. ;
van de Fliert, Reinaud ;
Dingemans, Peter M. ;
Klaassen, Rianne ;
de Haan, Lieuwe ;
van Amelsvoort, Therese ;
Linszen, Don H. .
SCHIZOPHRENIA RESEARCH, 2009, 109 (1-3) :60-65
[100]   Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex [J].
Watson, David J. G. ;
Loiseau, Florence ;
Ingallinesi, Manuela ;
Millan, Mark J. ;
Marsden, Charles A. ;
Fone, Kevin C. F. .
NEUROPSYCHOPHARMACOLOGY, 2012, 37 (03) :770-786